217 related articles for article (PubMed ID: 30630439)
1. Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy.
Ittiamornlert P; Ruengkhachorn I
BMC Cancer; 2019 Jan; 19(1):51. PubMed ID: 30630439
[TBL] [Abstract][Full Text] [Related]
2. Oncologic Outcomes of Stage IVB or Persistent or Recurrent Cervical Carcinoma Patients Treated With Chemotherapy at Siriraj Hospital: Thailand's Largest Tertiary Referral Center.
Ruengkhachorn I; Leelaphatanadit C; Therasakvichya S; Hunnangkul S
Int J Gynecol Cancer; 2016 Jul; 26(6):1154-61. PubMed ID: 27051060
[TBL] [Abstract][Full Text] [Related]
3. Prechemotherapy neutrophil : lymphocyte ratio is superior to the platelet : lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy.
Ji WH; Jiang YH; Ji YL; Li B; Mao WM
Dis Esophagus; 2016 Jul; 29(5):403-11. PubMed ID: 25625421
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Use of Pretreatment Hematologic Parameters in Patients Receiving Definitive Chemoradiotherapy for Cervical Cancer.
Onal C; Guler OC; Yildirim BA
Int J Gynecol Cancer; 2016 Jul; 26(6):1169-75. PubMed ID: 27206286
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Survival in Patients With FIGO Stage IVB Cervical Cancer.
Sasano T; Mabuchi S; Kuroda H; Takahashi R; Kozasa K; Isohashi F; Yoshioka Y; Ogawa K; Kimura T
Int J Gynecol Cancer; 2016 Mar; 26(3):528-33. PubMed ID: 26825839
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment neutrophil-lymphocyte and platelet-lymphocyte ratio predict clinical outcome and prognosis for cervical Cancer.
Zhu M; Feng M; He F; Han B; Ma K; Zeng X; Liu Z; Liu X; Li J; Cao H; Liang Y; Jia C; Zhang L
Clin Chim Acta; 2018 Aug; 483():296-302. PubMed ID: 29758203
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
Miao Y; Yan Q; Li S; Li B; Feng Y
Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Hwang JH; Lim MC; Seo SS; Kang S; Park SY; Kim JY
Arch Gynecol Obstet; 2012 Jun; 285(6):1685-93. PubMed ID: 22173823
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment C-reactive protein/albumin ratio is associated with poor survival in patients with stage IB-IIA cervical cancer.
Zhang W; Liu K; Ye B; Liang W; Ren Y
Cancer Med; 2018 Jan; 7(1):105-113. PubMed ID: 29193777
[TBL] [Abstract][Full Text] [Related]
10. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios do not predict survival in patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy.
Wang D; Wu M; Feng FZ; Huang HF; Yang JX; Shen K; Xiang Y
Chin Med J (Engl); 2013; 126(8):1464-8. PubMed ID: 23595378
[TBL] [Abstract][Full Text] [Related]
12. Posterior cervical lymph node metastasis as the valuable prognostic factor for stage IVA/IVB nasopharyngeal carcinoma treated with induction chemotherapy followed by concurrent chemo-radiotherapy.
Thephamongkhol K; Setakornnukul J; Rojwatkarnjana S; Chansilpa Y
Int J Biol Markers; 2014 Dec; 29(4):e387-94. PubMed ID: 25198554
[TBL] [Abstract][Full Text] [Related]
13. Preoperative neutrophil-lymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery.
Zhang Y; Wang L; Liu Y; Wang S; Shang P; Gao Y; Chen X
Int J Gynecol Cancer; 2014 Sep; 24(7):1319-25. PubMed ID: 25033256
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
15. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma.
Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kohno T; Shimizu C; Ando M; Kasamatsu T; Fujiwara Y
Oncol Rep; 2008 Feb; 19(2):497-503. PubMed ID: 18202800
[TBL] [Abstract][Full Text] [Related]
18. Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.
Templeton AJ; Knox JJ; Lin X; Simantov R; Xie W; Lawrence N; Broom R; Fay AP; Rini B; Donskov F; Bjarnason GA; Smoragiewicz M; Kollmannsberger C; Kanesvaran R; Alimohamed N; Hermanns T; Wells JC; Amir E; Choueiri TK; Heng DY
Eur Urol; 2016 Aug; 70(2):358-64. PubMed ID: 26924770
[TBL] [Abstract][Full Text] [Related]
19. Neutrophilia in locally advanced cervical cancer: A novel biomarker for image-guided adaptive brachytherapy?
Escande A; Haie-Meder C; Maroun P; Gouy S; Mazeron R; Leroy T; Bentivegna E; Morice P; Deutsch E; Chargari C
Oncotarget; 2016 Nov; 7(46):74886-74894. PubMed ID: 27713124
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic analysis of stage Ⅰb2 andⅡa2 cervical squamous cancer without high risk factors treated with neo-adjuvant chemotherapy and radical hysterectomy].
Li PP; Li B; Wang YT; Liu SH; Zhang YN; Zhang R; Bai P; Li XG; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2018 Apr; 53(4):248-256. PubMed ID: 29747270
[No Abstract] [Full Text] [Related]
[Next] [New Search]
